Literature DB >> 2448381

Effects of murine recombinant interleukin 1 alpha on the host response to bacterial infection.

C J Czuprynski1, J F Brown, K M Young, A J Cooley, R S Kurtz.   

Abstract

The effects of exogenously administered rIL-1 alpha on elimination of viable listeriae from the liver and spleen during the course of a primary Listeria monocytogenes infection was studied. Similar numbers of L. monocytogenes were recovered from rIL-1 alpha-treated and control mice at up to 24 h after infection; however, by 48 h after infection more than 1 log10 fewer viable L. monocytogenes were recovered from the spleens of rIL-1 alpha-treated mice than from Listeria-infected controls. The difference in bacterial burden between IL-1 alpha-treated and control mice increased with time; by 7 days after infection viable L. monocytogenes had been eliminated from most rIL-1 alpha-treated mice, whereas control mice still harbored 10(4) to 10(5) L. monocytogenes per spleen and liver. Histopathologic examination confirmed that rIL-1 alpha-treated mice suffered considerably less damage to the spleen, liver, lung, and brain than did control mice. To determine whether rIL-1 alpha-mediated protection indirectly by augmenting the release of other cytokines, we determined serum levels of colony-stimulating activity and IFN activity in rIL-1 alpha-treated and control Listeria-infected mice. Treatment with rIL-alpha elicited an early burst of serum colony-stimulating activity as compared with sera from Listeria-infected control mice. These data suggest that exogenous administration of rIL-1 initiates release of colony-stimulating activity, and perhaps other cytokines, that accelerate the protective response of the infected host. Prophylactic augmentation of antimicrobial resistance by administration of rIL-1 alpha may be worthy of further evaluation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448381

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Chlamydia trachomatis pneumonia induces in vivo production of interleukin-1 and -6.

Authors:  D M Magee; J G Smith; C A Bleicker; C J Carter; L F Bonewald; J Schachter; D M Williams
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

Review 2.  Use of immune modulators in nonspecific therapy of bacterial infections.

Authors:  M T Vogels; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  In vivo IL-1 potentiates both specific and non-specific arms of immune response to infection.

Authors:  C Cheers; Y F Zhan; P J Egan
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

4.  Effects of recombinant human interleukin-6 alone and in combination with recombinant interleukin-1 alpha and tumor necrosis factor alpha on antibacterial resistance in mice.

Authors:  C J Czuprynski; M Haak-Frendscho; N Maroushek; J F Brown
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  Interleukin-1 is involved in mouse resistance to Mycobacterium avium.

Authors:  M Denis; E Ghadirian
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

6.  Antibody-mediated enhancement of Legionella pneumophila-induced interleukin 1 activity.

Authors:  R H Widen; C A Newton; T W Klein; H Friedman
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

7.  A membrane vesicle/ribosome preparation from Serratia marcescens elicits peritoneal exudate cells expressing both tumoricidal and bactericidal activity.

Authors:  C McCall; L Weimer; S Baldwin; D W Riches; B Canono; P A Campbell
Journal:  Inflammation       Date:  1992-08       Impact factor: 4.092

8.  Effects of in vivo administration of anti-IL-10 monoclonal antibody on the host defence mechanism against murine Salmonella infection.

Authors:  T Arai; K Hiromatsu; H Nishimura; Y Kimura; N Kobayashi; H Ishida; Y Nimura; Y Yoshikai
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

9.  Roles of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice.

Authors:  M T Vogels; C C Hermsen; H L Huys; W M Eling; J W van der Meer
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice.

Authors:  E Hirsch; V M Irikura; S M Paul; D Hirsh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.